Company: KVACU
Filing Date: 2025-12-22
Form Type: PRE 14A
Source: 0001213900-25-124633
Chunk: 17

Company: Keen Vision Acquisition Corp.
Filing Date: 2025-12-22
Form: PRE 14A
Chunk 17
---
, DAVIDKHANIAN,
Alex, DING, Yibing Peter, CHU, William and YU, Albert Cheung-Hoi are the nominees of directors of the Company who are standing for election
or re-election at the Annual General Meeting.

The table below sets forth
the name, age and position of each nominee for director.

| Name                  |     | Age |     | Title                                          |
| WONG, Kenneth Ka Chun |     |  53 |     | Chairman, Chief Executive Officer and Director |
| DAVIDKHANIAN, Alex    |     |  52 |     | Chief Financial Officer and Director           |
| DING, Yibing Peter    |     |  59 |     | Director                                       |
| CHU, William          |     |  52 |     | Director                                       |
| YU, Albert Cheung-Hoi |     |  71 |     | Director                                       |

The following sets forth
information regarding each nominee:

Mr. WONG, Kenneth Ka Chun.

Mr.
Kenneth Wong, our CEO and Chairman since September 2021, has over 25 years of experience in finance and operations, with a track record
of executing notable M&A deals. Since their inceptions in September 2011 and December 2008 respectively, Mr. Kenneth Wong has been
the founder, Chairman and CEO of both Keen Vision Capital (BVI) Limited, a single-family office specializing in PE investments with minority
stakes, which has a track record of successful exits in the high technology, agriculture, and consumer goods industries, and Keen Vision
International Limited, a PE investment firm targeting controlling or majority stakes. During Mr. Kenneth Wong’s time in both companies,
he has been managing fundraising process and operations, providing restructuring, strategic and listing advice for investee companies,
and all investments were executed with a view to exit via listing on an international stock exchange or trade sale. Mr. Kenneth Wong also
served as the Vice Chairman of Medera Inc. between November 2021 and March 2024.

Prior
to this from October 2002 to February 2004, Mr. Kenneth Wong was first the CFO of the Shanghai A-share listed pharmaceutical research&
development and manufacturing subsidiary Topsun Science and Technology Company Limited (SH600771), before becoming the Senior Vice President
of the Topsun Pharmaceutical Group from February 2004 to August 2008. During his time at Topsun, Mr. Kenneth Wong oversaw acquisitions